Fagron NV

DB:4A5 Stock Report

Market Cap: €1.4b

Fagron Valuation

Is 4A5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4A5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4A5 (€18.54) is trading below our estimate of fair value (€51.76)

Significantly Below Fair Value: 4A5 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4A5?

Key metric: As 4A5 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4A5. This is calculated by dividing 4A5's market cap by their current earnings.
What is 4A5's PE Ratio?
PE Ratio17.3x
Earnings€77.94m
Market Cap€1.35b

Price to Earnings Ratio vs Peers

How does 4A5's PE Ratio compare to its peers?

The above table shows the PE ratio for 4A5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.7x
ILM1 Medios
28.5x47.8%€366.3m
HAEK HAEMATO
7.5xn/a€68.0m
RHK RHÖN-KLINIKUM
18.8x7.5%€843.4m
NXU Nexus
44.1x17.1%€1.2b
4A5 Fagron
17.3x14.7%€1.4b

Price-To-Earnings vs Peers: 4A5 is good value based on its Price-To-Earnings Ratio (17.3x) compared to the peer average (24.7x).

Price to Earnings Ratio vs Industry

How does 4A5's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
4A5 17.3xIndustry Avg. 18.2xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4A5 is good value based on its Price-To-Earnings Ratio (17.3x) compared to the European Healthcare industry average (17.7x).

Price to Earnings Ratio vs Fair Ratio

What is 4A5's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4A5 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.3x
Fair PE Ratio19.5x

Price-To-Earnings vs Fair Ratio: 4A5 is good value based on its Price-To-Earnings Ratio (17.3x) compared to the estimated Fair Price-To-Earnings Ratio (19.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4A5 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€18.54
€22.24
+20.0%
7.9%€24.00€19.50n/a5
Nov ’25€18.50
€22.24
+20.2%
7.9%€24.00€19.50n/a5
Oct ’25€18.60
€22.24
+19.6%
7.9%€24.00€19.50n/a5
Sep ’25€19.04
€22.24
+16.8%
7.9%€24.00€19.50n/a5
Aug ’25€19.02
€21.70
+14.1%
6.8%€24.00€19.50n/a5
Jul ’25€18.38
€21.70
+18.1%
6.8%€24.00€19.50n/a5
Jun ’25€18.50
€21.70
+17.3%
6.8%€24.00€19.50n/a5
May ’25€18.14
€21.70
+19.6%
6.8%€24.00€19.50n/a5
Apr ’25€17.50
€21.58
+23.3%
5.7%€23.00€19.50n/a5
Mar ’25€17.97
€21.58
+20.1%
5.7%€23.00€19.50n/a5
Feb ’25€16.53
€20.38
+23.3%
6.3%€22.40€18.50n/a5
Jan ’25€16.69
€20.38
+22.1%
6.3%€22.40€18.50n/a5
Dec ’24€17.37
€20.38
+17.3%
6.3%€22.40€18.50n/a5
Nov ’24€16.59
€20.38
+22.8%
6.3%€22.40€18.50€18.505
Oct ’24€15.99
€21.10
+32.0%
15.0%€27.00€17.50€18.605
Sep ’24€16.41
€21.10
+28.6%
15.0%€27.00€17.50€19.045
Aug ’24€16.11
€21.33
+32.4%
19.6%€27.00€17.00€19.023
Jul ’24€15.19
€20.83
+37.2%
22.7%€27.00€15.50€18.383
Jun ’24€16.83
€20.83
+23.8%
22.7%€27.00€15.50€18.503
May ’24€16.80
€20.83
+24.0%
22.7%€27.00€15.50€18.143
Apr ’24€15.40
€20.83
+35.3%
22.7%€27.00€15.50€17.503
Mar ’24€15.26
€20.83
+36.5%
22.7%€27.00€15.50€17.973
Feb ’24€13.53
€20.17
+49.1%
19.2%€25.00€15.50€16.533
Jan ’24€13.15
€20.83
+58.4%
15.0%€25.00€17.50€16.693
Dec ’23€12.57
€20.83
+65.7%
15.0%€25.00€17.50€17.373
Nov ’23€12.63
€20.50
+62.3%
13.5%€25.00€17.50€16.594

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

CVS Health

US$69.3b

Provides health solutions in the United States.

CVS

US$50.67

7D

-4.0%

1Y

-19.2%

Shandong Weigao Group Medical Polymer

HK$20.4b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-9.5%

1Y

-41.3%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%